Archive

Virginia Cancer Specialists Practice Blog

March 06, 2018

Clinical Trial – Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, developing targeted cancer therapeutics, today announced that the initial patient successfully completed the first cycle 1 of treatment in its Phase 1b/2 multicenter trial of PCM-075 in combination with low-dose cytarabine (LDAC) in patients with Acute Myeloid Leukemia (AML). The patient tolerated the combination well and correlative analyses of blood samples, taken at specified time points, also indicated activity on leukemic blood cells.

“Our first patient on PCM-075 appears to be tolerating the drug regimen well and the observed decrease of blood leukemic cells during the treatment cycle is encouraging,” said Alex Spira, MD, PhD, FACP, Director of The Virginia Cancer Specialists Research Institute.

Acute Myeloid Leukemia (AML)

More… Read the Complete Press Release Here

Related Posts

Investigational Inhibitor of Active RAS Shows Clinical Promise - Alexander I. Spira, MD, PhD, FACP

Clinical Trials Search, Alex Spira MD PhD FACP, Clinical Trials and Research
October 16, 2023
Read More

Landmark Non-Small Cell Lung Cancer Study - Clinically Meaningful Improvement and Progression Free Survival, Alexander I. Spira, MD, PhD, FACP 

Lung Cancer Team, The Research Institute, Alex Spira MD PhD FACP, Clinical Trials and Research, Lung Cancer, Non-Small Cell Lung Cancer
September 28, 2023
Read More

A Rare Breakthrough in the Treatment of Colorectal Cancer Patients Harboring a KRAS mutation.

Alex Spira MD PhD FACP, Colon & Rectal Cancer, Clinical Trials and Research
March 7, 2023
Read More

NEXT-Virginia Opens Phase I Clinical Research Clinic for Oncology Patients in collaboration with Virginia Cancer Specialists

NEXT Oncology, The Research Institute, Alex Spira MD PhD FACP, Clinical Trials and Research, Press Releases
January 10, 2023
Read More

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C - Co-Author Alexandar Spira, MD, PhD, FACP

Alex Spira MD PhD FACP, Colon & Rectal Cancer
January 9, 2023
Read More

Advancements in Lung Cancer Treatment Provide Hope for Virginia Cancer Specialists Patients - Alexander I. Spira, MD, PhD, FACP

Lung Cancer Team, Alex Spira MD PhD FACP, Lung Cancer
November 10, 2022
Read More